187 related articles for article (PubMed ID: 28415714)
1. Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab.
Lee CK; Kim SS; Park S; Kim C; Heo SJ; Lim JS; Kim H; Kim HS; Rha SY; Chung HC; Park S; Jung M
Oncotarget; 2017 May; 8(19):31169-31179. PubMed ID: 28415714
[TBL] [Abstract][Full Text] [Related]
2. Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy.
Kadowaki S; Masuishi T; Eto T; Narita Y; Taniguchi H; Ura T; Ando M; Tajika M; Niwa Y; Yatabe Y; Muro K
Cancer Chemother Pharmacol; 2017 Oct; 80(4):807-813. PubMed ID: 28821938
[TBL] [Abstract][Full Text] [Related]
3. Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin.
Nishina T; Azuma M; Nishikawa K; Gotoh M; Bando H; Sugimoto N; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Mitome T; Kageyama H; Hyodo I
Gastric Cancer; 2019 Jan; 22(1):138-146. PubMed ID: 29948386
[TBL] [Abstract][Full Text] [Related]
4. [Relationship of early tumor shrinkage and depth of response with the prognosis and treatment effect of trastuzumab combined with chemotherapy as first-line treatment in advanced gastric cancer patients with epidermal growth factor receptor 2 positive].
Zhu N; Chen JQ; Yang MY; Cheng Y; Yuan Y
Zhonghua Zhong Liu Za Zhi; 2020 Oct; 42(10):869-875. PubMed ID: 33113630
[No Abstract] [Full Text] [Related]
5. Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type.
Xu C; Liu Y; Jiang D; Li Q; Ge X; Zhang Y; Huang J; Su J; Ji Y; Hou J; Lu S; Hou Y; Liu T
Oncotarget; 2017 May; 8(20):33185-33196. PubMed ID: 28388541
[TBL] [Abstract][Full Text] [Related]
6. Associations between early tumor shrinkage and depth of response and clinical outcomes in patients treated with 1st-line chemotherapy for advanced gastric cancer.
Osumi H; Takahari D; Shinozaki E; Chin K; Ogura M; Wakatsuki T; Ichimura T; Nakayama I; Matsushima T; Yamaguchi K
Gastric Cancer; 2018 Mar; 21(2):267-275. PubMed ID: 28584889
[TBL] [Abstract][Full Text] [Related]
7. Depth of Response and Early Tumor Shrinkage for Predicting Clinical Outcomes in HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab.
Che YQ; Zhang Y; Ou KP; Wang D; Shen D; Liu HY; Luo Y
Cancer Manag Res; 2020; 12():8527-8534. PubMed ID: 32982445
[TBL] [Abstract][Full Text] [Related]
8. A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy.
Li Q; Lv M; Jiang H; Wang Y; Yu S; Li W; Yu Y; Liu T
J Cancer Res Clin Oncol; 2020 Jan; 146(1):287-295. PubMed ID: 31667572
[TBL] [Abstract][Full Text] [Related]
9. Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer.
Cho JH; Lim JY; Cho JY
World J Gastroenterol; 2017 Nov; 23(41):7407-7414. PubMed ID: 29151694
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of Chemotherapy with Trastuzumab in Advanced Gastric Cancer].
Kawada J; Nakatsuka R; Motoori M; Miyazaki S; Danno K; Kubota M; Matsuda C; Nishikawa K; Fujitani K; Iwase K; Tsujinaka T; Tanaka Y
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2091-3. PubMed ID: 26805274
[TBL] [Abstract][Full Text] [Related]
11. Early Tumor Shrinkage and Depth of Response as Predictors of Favorable Treatment Outcomes in Patients with Metastatic Colorectal Cancer Treated with FOLFOX Plus Cetuximab (JACCRO CC-05).
Tsuji A; Sunakawa Y; Ichikawa W; Nakamura M; Kochi M; Denda T; Yamaguchi T; Shimada K; Takagane A; Tani S; Kotaka M; Kuramochi H; Furushima K; Koike J; Yonemura Y; Takeuchi M; Fujii M; Nakajima T
Target Oncol; 2016 Dec; 11(6):799-806. PubMed ID: 27306648
[TBL] [Abstract][Full Text] [Related]
12. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab.
Piessevaux H; Buyse M; Schlichting M; Van Cutsem E; Bokemeyer C; Heeger S; Tejpar S
J Clin Oncol; 2013 Oct; 31(30):3764-75. PubMed ID: 24043732
[TBL] [Abstract][Full Text] [Related]
13. Predictive Roles of HER2 Gene Amplification and Neutrophil-to-Lymphocyte Ratio on Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab-Based Chemotherapy.
Park JH; Yeo JH; Kim YS; Park I; Ahn HK; Shin DB; Lee WK; Yang JY; Kim HS; Sym SJ
Am J Clin Oncol; 2021 Jun; 44(6):232-238. PubMed ID: 33710139
[TBL] [Abstract][Full Text] [Related]
14. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
van Ramshorst MS; van der Heiden-van der Loo M; Dackus GM; Linn SC; Sonke GS
Breast Cancer Res Treat; 2016 Jul; 158(2):361-71. PubMed ID: 27357813
[TBL] [Abstract][Full Text] [Related]
15. Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study.
Gong IY; Verma S; Yan AT; Ko DT; Earle CC; Tomlinson GA; Trudeau ME; Krahn MD; Krzyzanowska MK; Brezden-Masley CB; Gavura S; Peacock S; Chan KK
Breast Cancer Res Treat; 2016 Jun; 157(3):535-44. PubMed ID: 27271767
[TBL] [Abstract][Full Text] [Related]
16. Prealbumin-to-Globulin Ratio Can Predict the Chemotherapy Outcomes and Prognosis of Patients with Gastric Cancer Receiving First-Line Chemotherapy.
Wang Z; Zhang L; Wang J; Wang Y; Dong Q; Piao H; Wang Q; Zhang J
J Immunol Res; 2020; 2020():6813176. PubMed ID: 32832571
[TBL] [Abstract][Full Text] [Related]
17. Early tumor shrinkage as a predictor of favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX.
Kaga Y; Sunakawa Y; Kubota Y; Tagawa T; Yamamoto T; Ikusue T; Uto Y; Miyashita K; Toshima H; Kobayashi K; Hisamatsu A; Ichikawa W; Sekikawa T; Shimada K; Sasaki Y
Oncotarget; 2016 Oct; 7(41):67314-67320. PubMed ID: 27634903
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study.
Li Q; Li H; Jiang H; Feng Y; Cui Y; Wang Y; Ji Y; Yu Y; Li W; Xu C; Yu S; Zhuang R; Liu T
Clin Transl Oncol; 2018 Jun; 20(6):695-702. PubMed ID: 29168107
[TBL] [Abstract][Full Text] [Related]
19. Elevated Neutrophil-to-Lymphocyte Ratio Predicts Survival in Patients with Advanced Gastric Cancer Treated with Trastuzumab Combination Chemotherapy.
Hwang GY; Baek DW; Cho HJ; Lee SJ; Chae YS; Kang BW; Lee IH; Kim JG; Seo AN; Bae HI; Park KB; Park JY; Kwon OK; Lee SS; Chung HY
Anticancer Res; 2018 May; 38(5):3151-3156. PubMed ID: 29715156
[TBL] [Abstract][Full Text] [Related]
20. Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807.
Ura T; Hironaka S; Tsubosa Y; Mizusawa J; Kato K; Tsushima T; Fushiki K; Chin K; Tomori A; Okuno T; Matsushita H; Kojima T; Doki Y; Kusaba H; Fujitani K; Seki S; Kitagawa Y
Esophagus; 2023 Apr; 20(2):272-280. PubMed ID: 36427158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
